CHUM Centre de Recherche

Montreal, Quebec H2X1R9

0 studies enrolling now · 5 studies all time

What they study most

Biliary Tract Cancer, Glioblastoma Multiforme, Multiple Sclerosis, Relapsing-Remitting, Parkinson Disease, Select Advanced Solid Tumors

Studies at this site

• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM — Completed
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors — Running, not enrolling
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer — Stopped early